Identifying biomarkers for radiation sensitivity in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to recruit patients with nasopharyngeal cancer, prostate cancer, or other cancers that are sensitive to radiotherapy, particularly those who have experienced severe side effects from such treatments. Blood and matched tumor-normal tissue samples will be collected from participants to analyze genetic and biochemical markers. The goal is to identify biomarkers that could predict individual sensitivity to radiation therapy, enhancing personalized treatment approaches in oncology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with severe side effects from radiotherapy
* Patients with a type of cancer that is associated with sensitivity to radiotherapy

Exclusion Criteria:

* Age of patient must be between 21 (inclusive) and 99 (exclusive)

Where it's running

• National Cancer Center Singapore
  Singapore, Singapore Recruiting

Study contacts

• Principal investigator: Melvin Chua, MD — National Cancer Centre, Singapore
• Study coordinator: Melvin Chua, MD
• Email: melvin.chua.l.k@singhealth.com.sg

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ImmunoPET imaging for solid tumors targeting Trop2

  This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.

  Recruiting Phase 2/3 RenJi Hospital · Shanghai · NCT06851663

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• A resource for collecting cancer data and biospecimens

  This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.

  Recruiting at 42 sites University of Nebraska · Greenwood Village, Colorado and 41 other locations · NCT02012699

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.